World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
75
Citations
22004
World Ranking
1977
National Ranking
7

Thomas J. Scriba publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Thomas J. Scriba sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 312 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Thomas J. Scriba D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas J. Scriba sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 75 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Thomas J. Scriba is affiliated with the University of Cape Town in South Africa and has an extensive research profile primarily focused on tuberculosis and immunology. Their work spans multiple interconnected fields of study, including medicine, immunology and microbiology, as well as subfields such as immunology, infectious diseases, epidemiology, surgery, and molecular biology.

Their research topics consistently revolve around tuberculosis research and epidemiology, mycobacterium research and diagnosis, immune cell function and interaction, diagnosis and treatment of tuberculosis, T-cell and B-cell immunology, immunodeficiency and autoimmune disorders, and immune responses and vaccinations.

Among their recent papers are:

  • Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening (2020, Nature Biotechnology)
  • RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response (2020, Scientific Reports)
  • Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial (2021, The Lancet Infectious Diseases)
  • S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis (2020, Journal of Clinical Investigation)
  • Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise (2024, The Lancet Respiratory Medicine)

Thomas J. Scriba frequently collaborates with a number of coauthors, including Mark Hatherill, Simon C. Mendelsohn, Humphrey Mulenga, Gerhard Walzl, and Elisa Nemes. These collaborations have contributed significantly to their body of work in tuberculosis and immunology.

The scientist's work is often published in venues such as bioRxiv (Cold Spring Harbor Laboratory), Frontiers in Immunology, The Journal of Immunology, SSRN Electronic Journal, and The Lancet Respiratory Medicine. This range of publication sources reflects the interdisciplinary nature and focus of their research.

Thomas J. Scriba's research contributions center on understanding immune mechanisms related to tuberculosis, advancing diagnostic signatures for disease risk, and improving preventive and treatment methods. Their work integrates genomic, immunologic, and clinical approaches to address the challenges posed by tuberculosis and related infectious diseases.

Best Publications

  • Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

    Michele D Tameris;Mark Hatherill;Bernard S Landry;Thomas J Scriba

  • Identifying specificity groups in the T cell receptor repertoire

    Jacob Glanville;Huang Huang;Allison Nau;Olivia Hatton

  • A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

    Daniel E Zak;Adam Penn-Nicholson;Thomas J Scriba;Ethan Thompson

  • Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

    Elisa Nemes;Hennie Geldenhuys;Virginie Rozot;Kathryn T Rutkowski

  • Immunological biomarkers of tuberculosis.

    Gerhard Walzl;Katharina Ronacher;Willem Hanekom;Thomas J. Scriba

  • Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

    Dereck R. Tait;Mark Hatherill;Olivier Van Der Meeren;Ann M. Ginsberg

  • Distinct, Specific IL-17- and IL-22-Producing CD4+ T Cell Subsets Contribute to the Human Anti-Mycobacterial Immune Response

    Thomas J. Scriba;Barbara Kalsdorf;Deborah-Ann Abrahams;Fatima Isaacs

  • Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns

    Benjamin M. N. Kagina;Brian Abel;Thomas J. Scriba;Elizabeth J. Hughes

  • Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening.

    Huang Huang;Chunlin Wang;Florian Rubelt;Thomas J. Scriba

  • Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis

    Olivier Van Der Meeren;Mark Hatherill;Videlis Nduba;Robert J Wilkinson

  • T cells and adaptive immunity to Mycobacterium tuberculosis in humans

    Luke D. Jasenosky;Thomas J. Scriba;Willem A. Hanekom;Willem A. Hanekom;Anne E. Goldfeld

  • T-cell activation is an immune correlate of risk in BCG vaccinated infants

    Helen A. Fletcher;Helen A. Fletcher;Margaret A. Snowden;Bernard Landry;Wasima Rida

  • COMPASS identifies T-cell subsets correlated with clinical outcomes

    Lin Lin;Greg Finak;Kevin Ushey;Chetan Seshadri

  • Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis

    Sara Suliman;Ethan G. Thompson;Jayne Sutherland;January Weiner rd

  • Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8 + T cells

    Lucy J. Walker;Yu-Hoi Kang;Matthew O. Smith;Hannah Tharmalingham

  • Bacillus Calmette-Guérin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles

    Andreia P. Soares;Thomas J. Scriba;Sarah Joseph;Ryhor Harbacheuski

  • Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

    Thomas J. Scriba;Michele Tameris;Nazma Mansoor;Erica Smit

  • A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes

    Roshni Roy Chowdhury;Francesco Vallania;Qianting Yang;Cesar Joel Lopez Angel

  • Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

    Thomas J Scriba;Adam Penn-Nicholson;Smitha Shankar;Tom Hraha

  • Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa

    Tony Hawkridge;Thomas J. Scriba;Sebastian Gelderbloem;Erica Smit

Frequent Co-Authors

Willem A. Hanekom
Willem A. Hanekom University College London
Gerhard Walzl
Gerhard Walzl Stellenbosch University
Helen McShane
Helen McShane University of Oxford
Helen A. Fletcher
Helen A. Fletcher London School of Hygiene & Tropical Medicine
Cheryl L. Day
Cheryl L. Day Emory University
Robert J. Wilkinson
Robert J. Wilkinson The Francis Crick Institute
Cecilia S. Lindestam Arlehamn
Cecilia S. Lindestam Arlehamn La Jolla Institute For Allergy & Immunology
Alessandro Sette
Alessandro Sette La Jolla Institute For Allergy & Immunology
Stefan H. E. Kaufmann
Stefan H. E. Kaufmann Max Planck Institute for Infection Biology
W. Henry Boom
W. Henry Boom Case Western Reserve University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related online degrees can open diverse career paths in healthcare and research. Many individuals transition from general science studies into nursing, a field closely linked to immunological principles. If you’re starting without a nursing background, consider online BSN programs for non nurses, designed to build foundational nursing skills efficiently.

Those who want to expedite their education might explore accelerated nursing programs near me. These programs offer intensive coursework that transforms prior academic credits or experience into a quicker path to becoming a registered nurse, ideal for individuals shifting careers or advancing in health sciences.

For entry-level nursing roles, easy admission LPN programs provide accessible options to start clinical practice soon. Licensed Practical Nurse programs are shorter and often have simpler entry requirements, making them attractive for those eager to begin patient care roles related to immunology treatments.

Finally, for advanced practice roles, investigating which nurse practitioner program is easiest can help prospective students find manageable pathways to becoming nurse practitioners. These advanced degrees enable specialization in immunology-related fields, including infection control and immunotherapy management.

Best Scientists Citing Thomas J. Scriba

Trending Scientists

Recently Published Articles